While treatment of Ph+ ALL cells with PROTAC YX-2-107 promotes the preferential degradation of CDK6 over CDK4 in Ph+ ALL cells, treatment with palbociclib induced an increase in the levels of CDK6 that is likely to contribute to the development of palbociclib resistance [129,131]. The gene discussed is CDK4; the disease is acute lymphoblastic leukemia.